Skip to main content

Advertisement

Log in

New oral antidiabetic agents

  • WARD MEDICINE
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The pathophysiology of hyperglycemia in type 2 diabetes (T2DM) involves 3 main defects: insulin deficiency, excess hepatic glucose output, and insulin resistance. Oral anti-diabetic agents act in a variety of ways. These include agents that stimulate insulin secretion, reduce hepatic glucose production, delay digestion and absorption of intestinal carbohydrate or improve insulin action. Because of improved knowledge of pathophysiology, new drugs with mechanisms of action focussed on specific pathophysiological alterations have appeared, in order to utilize all the possibilities of treating this condition. Here, we focus on the new agents used in the latest years and the overcoming ones in future, in particular incretin-based therapies, drugs inhibiting kidney glucose reabsorption (SGLT2 inhibitors), and glucokinase activators. The strategy for new drug development advocated here is to establish a broad range of anti-diabetic medicines with different mechanisms of action and potential opportunities for effective combination therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Krentz AJ, Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65:385–411

    Article  PubMed  CAS  Google Scholar 

  2. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719

    Article  PubMed  CAS  Google Scholar 

  3. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D, The GLAL Study Group (2005) Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28:544–550

    Article  PubMed  CAS  Google Scholar 

  4. Durbin RJ (2004) Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280–285

    Article  PubMed  CAS  Google Scholar 

  5. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796–2803

    Article  PubMed  CAS  Google Scholar 

  6. Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T (2004) Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ-deficient mice on a high-fat diet. Diabetes 53:2844–2854

    Article  PubMed  CAS  Google Scholar 

  7. Kendall DM (2006) Thiazolidinediones the case for early use. Diabetes Care 29:154–157

    Article  PubMed  CAS  Google Scholar 

  8. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33:428–433

    Article  PubMed  CAS  Google Scholar 

  9. Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275–286

    PubMed  CAS  Google Scholar 

  10. Trujillo J (2006) Incretin hormones in the treatment of type 2 diabetes. Formulary 41:130–141

    CAS  Google Scholar 

  11. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326–1335

    Article  PubMed  CAS  Google Scholar 

  12. Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32–43

    Article  PubMed  CAS  Google Scholar 

  13. Rahmoune H, Thomson PW, Ward JM (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427–3434

    Article  PubMed  CAS  Google Scholar 

  14. Bays H (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 25:671–681

    Article  PubMed  CAS  Google Scholar 

  15. Chao EC (2011) A paradigm shift in diabetes therapy–dapagliflozin and other SGT2 inhibitors. Discov Med 11:255–263

    PubMed  Google Scholar 

  16. Bedoya FJ, Matschinsky FM, Shimizu T, O’Neil JJ, Appel MC (1986) Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol Chem 261:10760–10764

    PubMed  CAS  Google Scholar 

  17. Grimsbt J, Sarabu R, Corbett WL et al (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370–373

    Article  Google Scholar 

  18. Leighton B, Atkinson A, Coghlan MP (2005) Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 33:371–374

    Article  PubMed  CAS  Google Scholar 

  19. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399–416

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paolo Fornengo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cavallo Perin, P., Fornengo, P. New oral antidiabetic agents. Intern Emerg Med 6 (Suppl 1), 135 (2011). https://doi.org/10.1007/s11739-011-0677-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11739-011-0677-5

Keywords

Navigation